Sustainable vaccine development: a vaccine manufacturer's perspective

por Rappuoli, Rino, Hanon, Emmanuel
Publicado 2018

Broad Clade 2 Cross-Reactive Immunity Induced by an Adjuvanted Clade 1 rH5N1 Pandemic Influenza Vaccine

por Leroux-Roels, Isabel, Bernhard, Roger, Gérard, Pascal, Dramé, Mamadou, Hanon, Emmanuel, Leroux-Roels, Geert
Publicado 2008

A vaccine manufacturer’s approach to address medical needs related to seasonal and pandemic influenza viruses

por Baras, Benoit, Bouveret, Nancy, Devaster, Jeanne‐Marie, Fries, Louis, Gillard, Paul, Sänger, Roland, Hanon, Emmanuel
Publicado 2008

Vaccinology in the post−COVID-19 era

por Rappuoli, Rino, De Gregorio, Ennio, Del Giudice, Giuseppe, Phogat, Sanjay, Pecetta, Simone, Pizza, Mariagrazia, Hanon, Emmanuel
Publicado 2021

H5N1 Influenza Vaccine Formulated with AS03(A) Induces Strong Cross-Reactive and Polyfunctional CD4 T-Cell Responses

por Moris, Philippe, van der Most, Robbert, Leroux-Roels, Isabel, Clement, Frédéric, Dramé, Mamadou, Hanon, Emmanuel, Leroux-Roels, Geert G., Van Mechelen, Marcelle
Publicado 2010

Developing Vaccines for SARS-CoV-2 and Future Epidemics and Pandemics: Applying Lessons from Past Outbreaks

por Billington, John, Deschamps, Isabelle, Erck, Stanley C., Gerberding, Julie L., Hanon, Emmanuel, Ivol, Sabrina, Shiver, John W., Spencer, Julia A., Van Hoof, Johan
Publicado 2020

Cross-Protection against Lethal H5N1 Challenge in Ferrets with an Adjuvanted Pandemic Influenza Vaccine

por Baras, Benoît, Stittelaar, Koert J., Simon, James H., Thoolen, Robert J. M. M., Mossman, Sally P., Pistoor, Frank H. M., van Amerongen, Geert, Wettendorff, Martine A., Hanon, Emmanuel, Osterhaus, Albert D. M. E.
Publicado 2008